FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Eko Murmur Smart Stethoscope Software Cleared

FDA clears an Eko 510(k) for its Eko Murmur Analysis Software for use in its smart stethoscope for detecting and characterizing murmurs.

Medical Devices

Use Swab Samples of Lesions to Detect Monkeypox: FDA

An FDA safety communication advises that testing for monkeypox virus should use swab samples taken directly from a lesion to avoid false test results.

Federal Register

FDA Revokes EUA on Covid Detection Kit

Federal Register notice: FDA revokes the emergency use authorization issued to ScienCell Research Laboratories for its ScienCell SARSCoV2 Coronavirus ...

Federal Register

Guide on Instructions for Use Patient Labeling

Federal Register notice: FDA makes available a final guidance entitled Instructions for UsePatient Labeling for Human Prescription Drug and Biological...

Human Drugs

Provepharm NDA for Bludigo Approved

FDA approves a Provepharm NDA for Bludigo (indigotindisulfonate sodium), a diagnostic dye indicated for use as a visualization aid in the cystoscopic ...

Human Drugs

Hospira Recalls 1 Propofol Lot

Hospira recalls one lot of propofol injectable emulsion due to the presence of a visible particulate in a single retained vial from the lot.

Medical Devices

FDA Wants Patient Safety Info on Software Functions

FDA solicits comments on software functions excluded from the medical device definition by the 21st Century Cures Act.

Human Drugs

Drug Instructions for Use Guidance

FDA publishes a guidance on the content and format of patient instructions for use documents for prescription drugs and biologics.

Federal Register

Genentechs Enspryng Regulatory Review Period

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Genentechs Enspryng (satralizumab-mwge).

Federal Register

Regulatory Review Period for Glaxos Blenrep

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for GlaxoSmithKlines Blenrep (belantamab mafodotin-...